Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
June 28 2024 - 7:55AM
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or
the "Company"), a clinical-stage biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, announces advancement
in its proprietary MEAI- based binge behavior regulator program
through the granting of patent approval in Hong Kong by the Hong
Kong Patent Office
The allowed claims are directed, among others to use a primary
amine aminoindan compound to regulate binge behavior. This includes
primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan
(MEAI), the company's innovative psychedelic molecule.
This latest patent builds upon Clearmind’s broad IP protection
in the psychedelic space, which now includes 28 granted patents
across 18 patent families, with patents granted in major
jurisdictions such as the US, Europe, China, India, and now Hong
Kong.
MEAI is a new psychoactive molecule that reduces the desire to
consume alcoholic beverages and provides a slight euphoric,
alcohol-like experience, with the potential to change the lives of
millions who struggle to drink in moderation. Clearmind’s
MEAI-based flagship treatment focuses on Alcohol Use Disorder and
weight loss, which is incredibly common and ranges from mild to
severe. It is characterized by a person’s inability to restrict
their alcohol consumption, despite negative social, occupational,
or health consequences. Clearmind’s MEAI may also be used to treat
binge drinking, a potentially deadly addiction.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
eighteen patent families including 28 granted patents. The Company
intends to seek additional patents for its compounds whenever
warranted and will remain opportunistic regarding the acquisition
of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the
symbol "CMND" and the Frankfurt Stock Exchange under the symbol
“CWY0.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.com
Telephone: (604) 260-1566US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. The Company cannot assure that any
patent will issue as a result of a pending patent application or,
if issued, whether it will issue in a form that will be
advantageous to the Company.Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F for the
fiscal year ended October 31, 2023 filed with the SEC.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Jul 2024 to Aug 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Aug 2023 to Aug 2024